Vancouver, British Columbia--(Newsfile Corp. - August 3, 2021) - BioCure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (FSE: 1WH ) (CURE or the Company) - BioCure Technology Inc. ("BioCure" or the "Company") is pleased to announce listing on the Frankfurt Stock Exchange as of August 2, 2021 and the completion of an issuer sponsored research report by Pitt Street Research.
BioCure Technology Inc. is pleased to announce that the company will begin trading on the Frankfurt Stock Exchange on August 2nd, 2021, under the following codes:
FSE Symbol: 1WH
The Frankfurt Stock Exchange ranks third globally in terms of volume of trading behind the New York Stock Exchange and the Nasdaq Stock Market and will provide BioCure Technology Inc. wider access to European and other international investors. The Frankfurt Stock Exchange is another exciting component of BioCure's public market strategy and will make it easier for Europeans to invest.
The Frankfurt Stock Exchange accounts for over 90 per cent of the volume of all German stock exchanges and represents a large share of the European market. The Frankfurt Stock Exchange has more than 250 international trading institutions and more than 4,500 traders. Investors directly connected to the Frankfurt Stock Exchange represent 35 percent of the world's investment capital
The Company had engaged Pitt Street Research, https://www.pittstreetresearch.com/ ("Contractor") to provide an issuer sponsored research report which has been completed.
The report can be found on our website at biocuretechnologyinitiationreportpitt-research-29july2021.pdf
Pitt Street Research helps listed companies expand their investor base and help investors better understand the listed companies. Pitt Street Research's experienced equities analysts produce research reports on listed companies as well as interviews with company management. These insights are shared with investors around the world to help them better understand these companies by providing context around companies' news flow and announcements.
Should investors also wish to join the company's mailing list please email firstname.lastname@example.org.
BioCure is a leading biotech company developing its CAR-T cell therapy for leukemia, lung, breast and pancreatic cancer. BioCure, headquartered in Korea, has joint venture partners in Asia and Europe with planned clinical trials commencing in 2021. BioCure is in the process of pre-clinical trials of five major biosimilar products in South Korea, including Interferon Beta 1b, PEG- Filgrastim as well as Ranibizumab. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis ("MS") Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes.
ON BEHALF OF THE BOARD OF DIRECTORS
/S/ "SANG MOK LEE"
CEO and Director
For further information, please contact:
BioCure Technology Inc. Telephone: 604-609-7146, or email@example.com
Certain statements in this news release, which are not historical in nature, constitute "forward-looking statements" within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited to, statements or information concerning the Company's proposed activities under the Agreement and the expectations of the Company regarding funding payments due pursuant to the Agreement. These statements reflect management's current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward-looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place undue reliance on forward-looking statements. Neither the Canadian Securities Exchange (the "CSE") nor the Investment Industry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/91974